M&A Trend Picks Up Steam

The beat goes on as Amgen agrees to buy Micromet (MITI $10.95) for $1.16B.Micromet is focused on treatment  of hematologic malignancies with its BiTE monoclonal antibody platform and has four clinical stage  product candidates. The stock was $5 on November 25 ,2011.

Micromet was added to the Rayno Life Science Portfolio on 2/2/09 at a price of $4.

This is beginning to feel like the biotech market of 1999.

%d bloggers like this: